VSTM - Verastem, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
4.33
+0.36 (+9.07%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.97
Open3.85
Bid0.00 x 0
Ask0.00 x 0
Day's Range4.14 - 4.37
52 Week Range1.08 - 5.71
Volume1,290,081
Avg. Volume752,265
Market Cap175.319M
Beta3.11
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Options Traders Expect Huge Moves in Verastem (VSTM) Stock
    Zacks21 days ago

    Options Traders Expect Huge Moves in Verastem (VSTM) Stock

    Surging level of implied volatility makes Verastem (VSTM) stock lucrative to the investors.

  • Associated Presslast month

    Verastem reports 3Q loss

    On a per-share basis, the Needham, Massachusetts-based company said it had a loss of 61 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • TheStreet.com3 months ago

    Verastem Shares Are Exploding 50% -- Here's Why

    The Boston firm unveils positive results from its Phase 3 study of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

  • Reuters3 months ago

    Verastem's blood cancer drug succeeds in late-stage trial

    Verastem Inc said on Wednesday its drug to treat some types of blood cancer met the main goal of a late-stage study, sending the U.S. drug developer's shares up as much as 44.5 percent. Verastem said its drug, duvelisib, reduced the risk of disease progression or death in patients by 48 percent when compared with the current standard of care, Novartis's Arzerra. The oral drug was tested in 319 patients suffering from chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who did not respond to initial treatment or whose cancer had relapsed.

  • Implied Volatility Surging for Verastem (VSTM) Stock Options
    Zacks4 months ago

    Implied Volatility Surging for Verastem (VSTM) Stock Options

    Verastem (VSTM) needs Investors to pay close attention to the stock based on moves in the options market lately.

  • Verastem (VSTM) Shows Strength: Stock Adds 42% in Session
    Zacks5 months ago

    Verastem (VSTM) Shows Strength: Stock Adds 42% in Session

    Verastem, Inc. (VSTM) shares jumped almost 42% in the last trading session.

  • Benzinga6 months ago

    Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data

    The 2017 American Society of Clinical Oncology annual meeting is taking place in Chicago from last Friday through Tuesday. There have already been several companies that have updated shareholders with ...

  • Associated Press7 months ago

    Verastem reports 1Q loss

    The Needham, Massachusetts-based company said it had a loss of 35 cents per share. Losses, adjusted for stock option expense, came to 32 cents per share. The results surpassed Wall Street expectations. ...

  • Benzinga11 months ago

    Verastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors

    Verastem Inc (NASDAQ: VSTM ) is a biopharmaceutical company that focuses on discovering and developing therapies for the treatment of patients with cancer. Verastem acquired a license agreement from Infinity ...